Skip Nav Destination
Issues
Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer
Cynthia Villarreal-Garza; Ana S. Ferrigno; Alejandro Aranda-Gutierrez; Paul H. Frankel; Nora H. Ruel; Alan Fonseca; Steven Narod; Yanin Chavarri-Guerra; Erika Sifuentes; Maria Cristina Magallanes-Hoyos; Josef Herzog; Danielle Castillo; Rosa M. Alvarez-Gomez; Alejandro Mohar-Betancourt; Jeffrey N. Weitzel
Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics
Yang Gao; Elena B. Kabotyanski; Jonathan H. Shepherd; Elizabeth Villegas; Deanna Acosta; Clark Hamor; Tingting Sun; Celina Montmeyor-Garcia; Xiaping He; Lacey E. Dobrolecki; Thomas F. Westbrook; Michael T. Lewis; Susan G. Hilsenbeck; Xiang H.-F. Zhang; Charles M. Perou; Jeffrey M. Rosen
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.